Co-Prenessa tablets 4mg/1.25mg №10x3

Co-Prenessa Tablets 4mg/1.25mg: A Powerful Antihypertensive Combination for Effective Blood Pressure Control

h2 { font-size: 2em; } h3 { font-size: 1.5em; } p { line-height: 1.5; } ul { list-style: disc; margin-left: 2em; } li { margin-bottom: 0.5em; }

Co-Prenessa Tablets 4mg/1.25mg: A Powerful Antihypertensive Combination for Effective Blood Pressure Control

Description:

Co-Prenessa tablets are a fixed-dose combination medication containing perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor, and indapamide, a thiazide-like diuretic. This unique blend provides a synergistic antihypertensive effect, effectively lowering both systolic and diastolic blood pressure in patients with primary arterial hypertension.

Composition:

• Co-Prenessa 2mg/0.625mg Tablets: Each tablet contains 2mg perindopril erbumine and 0.625mg indapamide.
• Co-Prenessa 4mg/1.25mg Tablets: Each tablet contains 4mg perindopril erbumine and 1.250mg indapamide.

Pharmacological Properties:

Co-Prenessa works by combining the actions of its two active ingredients:

• Perindopril: Blocks the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor, leading to vasodilation, reduced blood pressure, and improved cardiac function.
• Indapamide: Inhibits sodium reabsorption in the kidneys, increasing urine output and reducing blood volume, ultimately lowering blood pressure.

Clinical Benefits:

• Effective Blood Pressure Control: Co-Prenessa provides a sustained, dose-dependent reduction in both systolic and diastolic blood pressure, lasting for 24 hours.
• Synergistic Effect: The combination of perindopril and indapamide offers a greater antihypertensive effect compared to either drug used alone.
• Improved Cardiac Function: Co-Prenessa reduces afterload and preload, improving heart function, particularly beneficial for patients with heart failure.
• Long-Term Efficacy: Regular use of Co-Prenessa maintains blood pressure control without causing tachyphylaxis or withdrawal syndrome.

Dosage and Administration:

• Co-Prenessa 2mg/0.625mg Tablets: The usual dose is 1 tablet once daily, preferably taken in the morning before meals. The dose may be increased to 2 tablets daily if necessary.
• Co-Prenessa 4mg/1.25mg Tablets: This dosage is indicated when blood pressure control cannot be achieved with the 2mg/0.625mg tablets. The usual dose is 1 tablet once daily, taken in the morning before meals.

Indications:

• Primary Arterial Hypertension: Co-Prenessa is indicated for the treatment of high blood pressure in adults.

Contraindications:

• Hypersensitivity: Co-Prenessa is contraindicated in individuals with known hypersensitivity to perindopril, indapamide, or other sulfonamides.
• Renal Impairment: Co-Prenessa is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min).
• Pregnancy: Co-Prenessa is contraindicated during the second and third trimesters of pregnancy.
• Lactation: Co-Prenessa is contraindicated during breastfeeding.
• Other: Co-Prenessa is also contraindicated in patients with hepatic encephalopathy, severe hepatic impairment, hypokalemia, and simultaneous use with antiarrhythmic drugs that prolong the QT interval.

Precautions:

• Renal Function: Co-Prenessa should be used with caution in patients with moderate renal impairment (creatinine clearance 30-60 ml/min), and dose adjustments may be necessary.
• Hepatic Function: Co-Prenessa should be used with caution in patients with moderate hepatic impairment.
• Hypokalemia: Co-Prenessa may cause hypokalemia. Regular monitoring of potassium levels is important, particularly in patients at risk.
• Hypotension: Co-Prenessa may cause hypotension. Patients should be monitored for signs and symptoms of low blood pressure, especially during the initial stages of treatment.
• Electrolyte Imbalances: Co-Prenessa can affect electrolyte balance. Regular monitoring of sodium and potassium levels is recommended.
• Pregnancy and Lactation: Co-Prenessa is contraindicated in pregnancy and lactation.
• Children and Adolescents: The safety and efficacy of Co-Prenessa in children and adolescents have not been established.

Side Effects:

The most common side effects associated with Co-Prenessa include:

• Headache
• Dizziness
• Fatigue
• Cough
• Hypotension
• Hypokalemia
• Gastrointestinal disturbances: Nausea, vomiting, abdominal pain, diarrhea, constipation.

Interactions:

Co-Prenessa may interact with other medications. It is important to inform your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements.

Overdose:

In case of overdose, seek immediate medical attention.

Storage:

Store Co-Prenessa tablets at room temperature, in a dry place, and out of reach of children.

Please note: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

Keywords:

Co-Prenessa, perindopril, indapamide, antihypertensive, hypertension, high blood pressure, blood pressure control, ACE inhibitor, diuretic, cardiovascular, heart health, side effects, dosage, contraindications, interactions, overdose, storage.